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Cognitive improvement in Alzheimer’s disease (AD) patients treated with intravenous 
immunoglobulin (IvIg) has been attributed to its antibodies to amyloid beta (Aβ).  We 
compared the concentrations of specific antibodies to soluble Aβ1-42 conformations, 
namely Aβ1-42 monomer and Aβ1-42 soluble oligomers, between three IvIg 
preparations, Gamunex, Gammagard, and Flebogamma.  To determine specific antibody 
concentrations to these Aβ1-42 conformations, nonspecific binding of the IvIg 
preparations to the Aβ reverse sequence, Aβ42-1, was subtracted.  These antibodies were 
measured in untreated IvIg preparations and also after they were treated to dissociate 
antibody-antigen complexes, because this procedure has been reported to increase the 
detectable levels of serum anti-Aβ antibodies.  Antibody levels to Aβ1-42 monomer were 
significantly higher in untreated Gamunex than in the other two IvIg preparations, and 
antibody-antigen dissociation increased the measured anti-Aβ monomer concentrations in 
Gamunex and Gammagard.  Dissociated Gamunex and Gammagard had higher anti-Aβ 
monomer levels than Flebogamma.  Generally similar results were found for antibodies 
to soluble Aβ1-42 oligomers, with the exception that after antibody-antigen dissociation, 
only Gammagard had significantly higher antibody levels than Flebogamma.  These 
differences in antibody concentrations to Aβ1-42 conformations (particularly to Aβ1-42 
soluble oligomers, thought to be the most neurotoxic conformation of soluble Aβ) and the 
increased availability of these antibodies after antibody-antigen complex dissociation 
have important implications for IvIg treatment of AD patients.  (Keywords: Alzheimer’s 
disease; Amyloid beta; Anti-amyloid beta antibodies; ELISA; Intravenous 
immunoglobulin; Oligomers) 
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1. Introduction  
     Amyloid beta (Aβ) is the major protein in senile plaques in the Alzheimer’s disease 
(AD) brain.  In a transgenic mouse model of AD, systemic vaccination with Aβ prevented 
plaque deposition and cognitive loss in young mice and reduced plaque counts and 
cognitive deficits in older animals [1].  These findings were extended in subsequent 
studies [2-4].  Similar results were also achieved with systemic administration of anti-Aβ 
antibodies [5-8], suggesting that antibodies to Aβ may be able to promote plaque 
clearance from the brain in AD patients.  This was confirmed by the finding of reduced 
brain Aβ content in eight AD patients who were vaccinated with Aβ in a phase I trial, 
although, surprisingly, there was no difference in the time required for patients to 
progress to severe dementia between vaccinated and placebo patients in this trial [9].  
This result differed from another study which suggested that Aβ vaccination may slow 
cognitive decline in AD patients [10].  Whether systemic antibodies to Aβ facilitate its 
removal by entering the brain, or via a “peripheral sink” mechanism [6] without entering 
the brain, is unclear.   
     Intravenous immunoglobulin (IvIg) is currently being investigated as a treatment for 
AD.  IvIg is composed of purified immunoglobulins (more than 95% is IgG, with only 
trace amounts of IgA or IgM [11]) pooled from thousands of clinically normal donors, 
and has long been used for treatment of selected autoimmune and immunodeficiency 
disorders [12,13].  It is currently approved by the Food and Drug Administration for six 
conditions [14], and is also commonly used in many “off-label” applications.  Improved 
cognitive scores were obtained in AD patients treated with IvIg in two short-term, open-
label trials [15,16].  A recent retrospective study also suggested that individuals who 
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receive IvIg have a reduced risk of developing AD [17].  While developing enzyme-
linked immunosorbent assays (ELISAs) to measure IvIg’s antibodies to the two soluble 
conformations of Aβ1-42, namely Aβ monomer and Aβ soluble oligomers, we found 
increased optical density (OD) readings not only when diluted IvIg preparations were 
incubated in wells previously coated with Aβ1-42, but also when they were incubated in 
wells coated with irrelevant proteins (i.e., the reverse Aβ sequence Aβ42-1 or bovine 
serum albumin [BSA]) or even buffer alone, compared to the standard negative control in 
which buffer was substituted for IvIg.  Although anti-Aβ antibodies in IvIg have been 
measured previously by ELISA [18-20], no controls for the specificity of antibody 
binding to Aβ were described in these studies; thus, the extent to which specific 
antibodies to Aβ1-42 were measured is unclear.  The objective of the present study, 
therefore, was to compare the concentrations of specific IgG to Aβ1-42 monomer and 
soluble oligomers between different IvIg preparations.  Because low pH dissociation of 
antibody-antigen complexes has been reported to increase the detectable levels of serum 
anti-Aβ antibodies [21], these experiments were performed with dissociated as well as 
untreated IvIg preparations.   
 
2. Materials and methods  
2.1. Production of Aβ monomer and soluble oligomers 
     Aβ1-42 (0.5 mg; AnaSpec, San Jose, CA) was disaggregated by suspending in 0.25 ml 
trifluoroacetic acid (hereafter, TFA; reagent grade TFA, Sigma-Aldrich, Inc., St. Louis, 
MO) followed by an equal volume of hexafluoro-2-propanol (Sigma-Aldrich).  After 
water bath sonication for 1 hr, it was aliquotted into 0.6 ml eppitubes (20 μl/tube), dried 
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with N2 gas for 90 min, and stored at –20o C.  To produce Aβ monomer, 20 μg of the 
disaggregated Aβ1-42 was resuspended by vortexing for 3 min in 0.6 ml HPLC-grade 
water, adjusted to pH 3.0 with TFA (hereafter, “TFA water”).  This was repeated twice 
more, yielding 1.8 ml of resuspended Aβ.  21.8 mg of Tris base (Trizma base, Sigma) 
was then added with vortexing to bring the Tris concentration to 100 mM.  The pH of this 
solution was adjusted to 8.8 by adding 12.1 N HCl.  This preparation, whose protein 
concentration was measured as 6 μg/ml with the Bio-Rad protein assay (data not shown), 
was centrifuged (12,000 rpm [11,752 x g] x 5 min, room temperature), passed through a 
0.2 μm filter (GHP Acrodisc 13 mm Syringe Filter with 0.2 μm GHP Membrane, Pall 
Life Sciences, East Hills, NY), and used immediately.  The Aβ reverse sequence, Aβ42-1 
(AnaSpec), was prepared in a similar manner.  Aβ oligomers were produced as described 
by Kayed et al. [22] with slight modifications.  60 μg of previously disaggregated Aβ1-42 
(and, as a negative control, Aβ42-1) was resuspended in 4.8 μl of 1% NH4OH, yielding a 
concentration of 2.8 mM.  This was sonicated in a water bath for 4 min, incubated at 
room temperature for 1 hr, and then diluted in phosphate buffered saline (PBS; 10 mM, 
pH 7.4, with 0.02% azide) to a final Aβ concentration of 45 μM.  It was used 
immediately or stored at 4o C for up to one week. 
 
2.2. Evaluation of Aβ conformations by Western blot 
     Aβ preparations were electrophoresed under reducing conditions through 4-20% Tris-
HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA).  20 μl of the 6 μg/ml monomer 
preparation (0.12 μg) was mixed with an equal volume of Laemmli Sample Buffer (Bio-
Rad), and then loaded into appropriate lanes; for the oligomer preparation, 10 μl of the 45 
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μM (203 μg/ml) preparation (2.03 μg) was mixed with an equal volume of Laemmli 
sample buffer and then loaded onto the gel.  After electrophoresis, the proteins were 
transferred to Westran S PVDF membranes (Whatman International Ltd., Maidstone, 
UK).  The membranes were then blocked with 10% non-fat dry milk in 0.01M PBS, pH 
7.4, filtered through qualitative filter paper (Whatman), for 1 hr at room temperature with 
agitation.  Membranes were incubated overnight at 4° C with agitation in mouse 
monoclonal anti-Aβ(1-16) 6E10 (Covance Research Laboratories, Berkeley, CA; 1:5,000 
dilution).  After incubation in horseradish peroxidase (HRP)-conjugated anti-mouse IgG 
(Vector Laboratories, Inc., Burlingame, CA; 1:10,000 dilution) for 1 hr at room 
temperature with agitation, membranes were developed in SuperSignal West Pico 
chemiluminescent substrate (Thermo Scientific, Rockford, IL).  Bands were detected on 
CL-XPosure film (Thermo Scientific).   
   
2.3. IvIg preparations 
     Three IvIg preparations were evaluated: Gamunex Immune Globulin Intravenous 
(Human), 10% (Talecris Biotherapeutics, Inc., Research Triangle Park, NC), Gammagard 
Liquid [Immune Globulin Intravenous (Human)] 10% (Baxter Healthcare Corp., 
Westlake Village, CA), and Immune Globulin Intravenous (Human) Flebogamma 5% 
DIF 2.5 g (Grifols Biologicals Inc., Los Angeles, CA). 
 
2.4. Dissociation of antibody-antigen complexes in IvIg preparations 
     The procedure described by Li et al. [21] for antibody-antigen dissociation (hereafter, 
“dissociation”) was followed with slight modifications.  40 μl of each IvIg preparation 
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was diluted 1:100 by adding 3,960 μl of dissociation buffer (0.01 M PBS, pH 7.2, with 
1.5% BSA and 0.2 M glycine, adjusted to pH 3.5 with glacial acetic acid).  After 20 min 
at room temperature, it was centrifuged (3,000 x g, 90 min) through a YM-30 filter 
(Amicon Ultra-4 Ultracel-30k, Millipore Corp., Billerica, MA).  Tris buffer (1 M, pH 9.0) 
was added to bring the retentate pH to 7.0, and PBS with 0.1% Tween-20 (Sigma) and 
1% BSA (hereafter, PBS-T-BSA) was added to bring the final volume of the retentate to 
4 ml.  This was stored at 4o C for up to one week.    
 
2.5. ELISA measurement of antibodies to Aβ monomer and soluble oligomers in IvIg 
preparations 
     Specific antibody concentrations to Aβ1-42 monomer and soluble oligomers were 
measured by ELISA in four to five experiments for each IvIg preparation, separately for 
the two Aβ conformations; in all, 27 experiments were performed.  IvIg preparations 
were randomized as to the order in which these experiments were performed.  Aβ 
monomer and oligomers were generated as described above, subjecting the Aβ reverse 
sequence Aβ42-1 to the same procedures in order to generate a negative control.  In 
experiments in which anti-Aβ monomer antibodies were measured, the monomer 
preparation and its reverse sequence, Aβ42-1, were incubated at a concentration of 6 
μg/ml in Tris buffer (0.1 M, pH 8.8) overnight at 4o C on a 96-well Nunc Maxisorp plate.  
In separate experiments in which IvIg’s anti-Aβ oligomer antibodies were measured, the 
oligomer preparation and reverse Aβ sequence were incubated on the plates overnight at 
0.9 μg/ml.  (In these latter experiments, additional wells were also incubated with an 
equal concentration of the monomer preparation.  Because densitometric analysis 
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indicated that approximately 30% of the total band intensity in the oligomer preparation 
was due to Aβ monomer [data not shown], after calculating the mean anti-monomer 
antibody concentration, 30% of this was subtracted from the specific antibodies to the 
oligomer preparation.)  Wells were then treated with SuperBlock (SuperBlock Blocking 
Buffer in PBS, Thermo Scientific) as per the manufacturer’s instructions, followed by 
untreated or dissociated IvIg preparations.  Untreated and dissociated Gamunex were 
diluted 1:1,000 in PBS-T-BSA, while Gammagard and Flebogamma were diluted 1:100.  
(These dilutions were chosen on the basis of preliminary experiments to determine which 
dilutions of each IvIg would result in similar OD readings in the linear portion of the 
standard curve.)  Three to six wells were incubated for each condition.  Four-fold 
dilutions of mouse monoclonal 6E10 anti-Aβ antibody (1:4,000 [250 ng/ml], 1:16,000 
[62.5 ng/ml], 1:64,000 [15.6 ng/ml], and 1:256,000 [3.9 ng/ml]) were included for the 
standard curve on each plate.  Secondary antisera were biotinylated goat anti-human IgG 
for wells previously incubated with IvIg preparations and biotinylated goat anti-mouse 
IgG for wells receiving mouse antibodies (both from Vector; dilution was 1:1,000 in 
PBS-T-BSA).  After incubation with streptavidin-alkaline phosphatase (Zymed 
Laboratories, Invitrogen, Carlsbad, CA; 1:1,000 in PBS-T), para-nitrophenol phosphate 
(Sigma) was added (5 mg in 40 ml of 1 M diethanolamine buffer, pH 9.8) and the plate 
was read at 405 nm with a Vmax kinetic microplate reader (Molecular Devices Corp., 
Sunnyvale, CA) until the standard curve OD reached 1.0.  Softmax Pro software version 
3.0 (Molecular Devices) was used to generate the best-fit plot of the standard curve, using 
the log-logit option.  To calculate specific anti-monomer antibody concentrations, the 
mean antibody concentration measured when each IvIg preparation was incubated on 
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wells previously coated with Aβ42-1 was subtracted from antibody concentrations 
measured on wells coated with an equal concentration of monomeric Aβ1-42.  
Calculation of specific antibodies to Aβ oligomers was performed as described above. 
  
2.6. Statistics  
     Data were analyzed from 27 experiments: five experiments for anti-Aβ monomer 
antibodies, and four experiments for anti-Aβ oligomer antibodies, for each of the three 
IvIg products.  Data from each experiment were adjusted for interassay variation by 
multiplying them by a normalization factor.  This factor was derived by first determining 
the observed (calculated) concentration, in each experiment, of the 1:64,000 dilution  
(= 15.6 ng/ml) of mouse monoclonal anti-Aβ antibody in the standard curve.  (This 
dilution was chosen because its OD value most closely approximated that of the diluted 
IvIg samples.)  The mean concentration (+ SEM) of this dilution of the antibody for all 
27 assays was 14.995 + 0.182 μg/ml, and the coefficient of variation was 6.3%.  To 
calculate the normalization factor for each plate, this mean value was divided by the 
observed concentration of this dilution on the plate.  Observations that were identified as 
outliers on graphical and statistical inspection were excluded from analysis.  The 
distribution of each data set was first analyzed to determine if it met the assumptions of 
the statistical tests proposed to analyze it.  Based on this assessment, either Student’s t-
test (two-tailed), Wilcoxon Two-Sample Test using t-approximation, Fixed Effects 
ANOVA with Least Squares analysis, or Kruskal-Wallis test was used to compare the 
mean concentrations or median scores of anti-monomer and anti-oligomer antibodies 
between untreated IvIg preparations, between dissociated IvIg preparations, and between 
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the untreated and dissociated forms of each IvIg preparation.  Post hoc pairwise 
comparisons were performed, when necessary, with Hochberg’s adjustment [23].   
P-values less than an alpha of 0.05 (probability of type I error) were considered 
statistically significant for all tests.  Statistical analysis was performed using SAS System 
for Windows version 9.2. 
 
3. Results   
3.1. Production of Aβ monomer and soluble oligomers 
     Aβ is supplied commercially as a lyophilized, trifluoracetic acid salt.  When PBS was 
added to this preparation, Aβ did not go into solution, in agreement with Burdick et al. 
[24] that Aβ1-42 is relatively insoluble at pH 7.4 and in aqueous media.  When Aβ 
previously disaggregated in our laboratory was first dissolved in TFA water (pH 3.0) and 
the pH was then adjusted to 7.0, only one band was generated in SDS PAGE gels (Fig. 1, 
lane A) and native gels (not shown).  This was assumed to represent monomeric Aβ 
(molecular weight = 4.5 kDa) because its molecular weight on the SDS PAGE gel was 
less than the lowest molecular weight standard, 7 kDa.  When disaggregated Aβ was 
resuspended in NH4OH and incubated for 1 hr before adjusting the pH to 7.4, multiple 
oligomeric bands were visualized on the SDS PAGE gel, although some monomer was 
also present (Fig. 1, lanes B and C).  Lower molecular weight bands were also evident in 
this preparation, probably representing Aβ fragments.  Our efforts to remove Aβ 
monomer from this latter preparation by selective molecular weight filtration, 
centrifugation, or treatment with insulin-degrading enzyme [25] were unsuccessful.    
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3.2. Specific antibodies in IvIg preparations to Aβ1-42 monomer  
     The ELISA standard curve for detection of specific antibodies to Aβ1-42 monomer is 
shown in Fig. 2.  The curve was generated with four-fold dilutions of mouse monoclonal 
antibody 6E10 (anti-Aβ1-16), and the lower limit of sensitivity of the assay was 
approximately 4 ng/ml.  The mean concentrations of specific antibodies in the three IvIg 
preparations, both untreated and after antibody-antigen dissociation, to Aβ1-42 monomer 
are shown in Fig. 3.  In untreated IvIg preparations, the highest concentration of these 
antibodies was detected in Gamunex (p = 0.0172 vs. both Flebogamma and Gammagard).  
Flebogamma’s anti-monomer antibodies were also higher than those in Gammagard.  
After dissociation of antibody-antigen complexes, Gamunex still contained the highest 
concentration of these antibodies, followed by Gammagard and then Flebogamma  
(p < 0.05 only for dissociated Gamunex vs. dissociated Flebogamma).  Dissociation 
significantly increased the detectable anti-monomer levels in Gamunex and Gammagard 
(both p = 0.0172 vs. their untreated forms), while decreasing it in Flebogamma  
(p = 0.0014).  The mean OD values for binding of the IvIg preparations to Aβ1-42 
monomer and to the Aβ reverse sequence Aβ42-1 are shown in Fig. 4, indicating the 
extensive nonspecific binding that was subtracted in order to calculate the specific anti-
Aβ1-42 antibody concentrations.   
 
3.3. Specific antibodies in IvIg preparations to Aβ1-42 soluble oligomers 
     The mean concentrations of anti-Aβ1-42 oligomer antibodies in IvIg preparations are 
shown in Fig. 5.  Results were generally similar to those for anti-monomer antibodies.  
Untreated Gamunex had the highest concentration of anti-oligomer antibodies  
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(p = 0.0172 vs. both Flebogamma and Gammagard).  Antibody-antigen dissociation 
significantly increased these antibodies in all three IvIg preparations, and dissociated 
Gammagard had significantly higher anti-oligomer antibodies than dissociated 
Flebogamma (p = 0.0081).  The mean OD values for IvIg binding to Aβ1-42 oligomers 
and the Aβ reverse sequence are shown in Fig. 6; the percentage of binding to Aβ1-42 
oligomers that was specific tended to be greater, particularly for Flebogamma and 
Gammagard, than their binding to Aβ1-42 monomers.   
 
4. Discussion 
     The encouraging results in the trials in which IvIg was administered to AD patients 
[15,16] suggest that IvIg may be of value for treatment of AD.  The investigators in these 
trials suggested that anti-Aβ antibodies might be responsible for IvIg’s benefits in AD 
patients.  However, other explanations are also possible; for example, IvIg has marked 
anti-inflammatory actions [12] which could have contributed to improvement in the AD 
patients.  In the present study, untreated Gammagard’s specific antibody levels to Aβ1-42 
monomer was lower than the other two IvIg preparations examined, and its specific 
antibody level to Aβ1-42 soluble oligomers was intermediate between Gamunex and 
Flebogamma.  The relatively low anti-Aβ levels in Gammagard suggest that its benefits 
in the AD trial in which it was administered [16] may not have been due solely to anti-Aβ 
antibodies.   
     Various approaches have been used to produce soluble Aβ oligomers [22,25-28].  Our 
results underscore the difficulties in producing a pure oligomer preparation.  In 
agreement with previous findings by Teplow [27], we were able to consistently produce 
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oligomers by initially disaggregating Aβ and then resuspending it in alkaline pH.  The 
oligomer preparation contained Aβ monomer as well. Our finding that all three IvIg 
preparations contained measurable levels of antibodies to Aβ oligomers even after 
subtracting out anti-monomer antibodies suggests that these preparations may contain 
some antibodies which recognize Aβ oligomers but not Aβ monomer, in agreement with 
the conclusions from a recent immunocytochemical study [29].   
     The surprisingly high levels of nonspecific binding of the IvIg preparations to the 
reverse sequence Aβ42-1, compared to their binding to Aβ1-42 monomer and oligomers, 
are shown in Figs. 4 and 6, respectively.  This nonspecific binding was typically almost 
as high as the specific binding to Aβ1-42, and in some experiments it equaled it.  Further 
investigation of the nature of this nonspecific binding, and how to reduce or prevent it, is 
beyond the scope of this study.  It should be noted, however, that there is extensive 
nonspecific binding of IvIg’s immunoglobulins when antibodies to Aβ are measured in 
the indirect ELISA, and this binding must be taken into account when calculating IvIg’s 
specific anti-Aβ antibody concentration. 
     The presence of antibodies to Aβ in IvIg preparations reflects the presence of these 
antibodies in serum and plasma in clinically normal individuals.  Numerous studies have 
compared the levels of these antibodies between non-cognitively impaired subjects and 
those with AD, but whether these antibodies increase, decrease, or remain unchanged in 
AD subjects is unclear [30-37].  Anti-Aβ antibodies in human serum are present in IgM 
as well as IgG, and the anti-Aβ titer for these antibodies has been reported to be higher in 
IgM than in IgG [20].  In the present study antibodies to Aβ were measured in IgG but 
not in IgM because IvIg contains only trace amounts of IgM [11].        
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     In conclusion, this study revealed differences in specific antibody levels to soluble 
Aβ1-42 conformations between IvIg preparations, as well as within IvIg preparations 
after antibody-antigen complex dissociation.  These findings could have important 
implications for treatment of AD patients with IvIg.  Among the untreated IvIg products, 
Gamunex had the highest concentration of anti-monomer antibodies, in agreement with 
findings presented at the ICAD 2006 meeting by Talecris Biotherapeutics, the 
manufacturer of Gamunex [38] (our measurements of anti-Aβ monomer antibodies were 
completed before we learned of these results), and also the highest level of anti-oligomer 
antibodies.  The relatively low specific antibody levels in Gammagard to both Aβ 
conformations were surprising in view of its success in the previously-mentioned AD 
clinical trial [16].  Our finding that antibody-antigen complex dissociation tended to 
increase the available levels of anti-Aβ antibodies in IvIg preparations suggests that this 
procedure might increase the ability of IvIg preparations to reduce brain Aβ and/or 
neutralize its neurotoxic actions, particularly those of Aβ soluble oligomers [39]. 
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Figure legends   
 
Fig. 1:  Western blots of Aβ1-42 preparations generated in various conditions.  Lane A: 
monomeric Aβ (MW 4.5 kDa) generated by resuspending lyophilized Aβ1-42 in TFA 
and hexafluoro-2-propanol to disaggregate it, followed by drying it with N2 gas, 
dissolving it in TFA water (pH 3.0), and adding Tris base and HCl to adjust the pH to 7.0.  
Lanes B and C: disaggregated Aβ, after resuspending in NH4OH, brief sonication,  
incubating for one hr at room temperature, and then adjusting to neutral pH.  (Total 
protein loaded: lane A, 0.2 μg; lane B, 1.0 μg; lane C, 2.0 μg.) 
  
Fig. 2:  ELISA standard curve with four-fold dilutions of mouse monoclonal antibody 
6E10 (anti-Aβ1-16) placed in wells previously coated with Aβ1-42 monomer.  The lower 
limit of sensitivity of the assay was approximately 4 ng/ml.  A similar standard curve was 
generated for binding of the antibody to the Aβ1-42 oligomer preparation. 
 
Fig. 3:  Mean concentrations of specific antibodies to Aβ1-42 monomer in each IvIg 
preparation.  Data shown are means + SEM from pooled data from five experiments  
(5-6 wells per condition in each experiment) for each IvIg preparation.  (GX = Gamunex, 
FG = Flebogamma, GG = Gammagard Liquid; ap < 0.05 vs. untreated Flebogamma; bp < 
0.05 vs. untreated Gammagard; cp < 0.05 vs. dissociated Gamunex; dp < 0.05 vs. 
dissociated Flebogamma)    
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Fig. 4:  Mean optical density (OD) values for binding of untreated and antibody-antigen-
dissociated IvIg preparations to Aβ1-42 monomer vs. the Aβ reverse sequence, Aβ42-1.   
The dilutions of the IvIg preparations were:  Gamunex, 1:1,000; Gammagard, 1:100; and 
Flebogamma, 1:100.  These dilutions were chosen to provide similar OD readings, in the 
linear part of the standard curve, for the untreated IvIg products.  The extensive binding 
to Aβ42-1 indicates that only a small percentage of IvIg’s binding to Aβ1-42 was actually 
specific.     
 
Fig. 5:  Mean concentrations of specific antibodies to Aβ1-42 oligomers in each IvIg 
preparation.  Data shown are means + SEM from pooled data from four experiments (3-6 
wells per condition in each experiment) for each IvIg preparation. (GX = Gamunex, FG = 
Flebogamma, GG = Gammagard Liquid; ap < 0.05 vs. untreated Flebogamma; bp < 0.05 
vs. untreated Gammagard; cp < 0.05 vs. untreated Gamunex; dp < 0.05 vs. dissociated 
Flebogamma)    
 
Fig. 6:  Mean optical density (OD) values for binding of untreated and antibody-antigen-
dissociated IvIg preparations to Aβ1-42 oligomers vs. the Aβ reverse sequence, Aβ42-1.  
The percentage of binding to Aβ1-42 oligomers that was specific tended to be greater for 
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